Rezorba in treatment of metastatic prostate cancer bone lesions
The main aim of the work described in this article is efficiency and safety estimation of Rezorba (zoledronic acid) in prostate cancer patients with bone metastasies (MTS). This drug suppresses osteoclast activity, does not render undesirable influence on formation, mineralization and mechanical properties of bone tissue, possesses the direct antineoplastic activity, which is efficient in metastatic disease.
- Read more about Rezorba in treatment of metastatic prostate cancer bone lesions
- Log in or register to post comments
- 25679 views